ConvaTec Group Plc

LSE CTEC.L

ConvaTec Group Plc EBT Margin for the year ending December 31, 2023: 7.81%

ConvaTec Group Plc EBT Margin is 7.81% for the year ending December 31, 2023, a 97.73% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • ConvaTec Group Plc EBT Margin for the year ending December 31, 2022 was 3.95%, a -46.76% change year over year.
  • ConvaTec Group Plc EBT Margin for the year ending December 31, 2021 was 7.42%, a -19.51% change year over year.
  • ConvaTec Group Plc EBT Margin for the year ending December 31, 2020 was 9.22%, a 791.60% change year over year.
  • ConvaTec Group Plc EBT Margin for the year ending December 31, 2019 was 1.03%, a -90.58% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
LSE: CTEC.L

ConvaTec Group Plc

CEO Mr. Karim Bitar
IPO Date Oct. 26, 2016
Location United Kingdom
Headquarters 3 Forbury Place
Employees 10,000
Sector Health Care
Industries
Description

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Similar companies

BEZ.L

Beazley plc

USD 9.61

1.44%

INF.L

Informa plc

USD 9.78

1.87%

GNS.L

Genus plc

USD 17.38

-3.70%

StockViz Staff

January 15, 2025

Any question? Send us an email